Total Funding
31
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
203119
Pfenex develops biosimilar therapeutics and novel vaccines for the treatment and prevention of critical human health issues.
Acquired by 
Ligand Pharmaceuticals
- Patrick Lucy: VP Business Development
James C. Gale: DirectorPast Role: Gruntal & Co, Head of Principal Investment Activities & Investment Banking
About the Company
Headquartered in San Diego, California, PfÄ“nex Inc. is a leading biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars. The Company's core technology, PfÄ“nex Expression Technology™, is a cutting edge protein expression
platform that utilizes the BSL-1 microorganism Pseudomonas fluorescens. PfÄ“nex Expression Technology™ combines an extensive toolbox of expression components with a robotically enabled high throughput parallel strain screening technology, delivering unprecedented speed and success in identifying protein production strains expressing high titers of soluble active protein.
